Retraction: HMGB2 upregulation promotes the progression of hepatocellular carcinoma cells through the activation of ZEB1/vimentin axis
Retraction to: J Gastrointest Oncol 2023;14:2178-91
The Editors have retracted this article titled “HMGB2 upregulation promotes the progression of hepatocellular carcinoma cells through the activation of ZEB1/vimentin axis” (1) published in Journal of Gastrointestinal Oncology based on concerns about some of the data presented in this article, which were brought to the attention of the Editors. Specifically, the image panel of some figures appears to overlap with the some figure images of the article published in Oncotarget (2). After reviewing the raw data files provided by the authors, the Editors no longer have confidence in the reliability of the findings and conclusions presented in this manuscript.
The authors did not respond to correspondence from the Publisher regarding this retraction.
Footnote
Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.
References
- Lu K, Zhao T, Yang L, et al. HMGB2 upregulation promotes the progression of hepatocellular carcinoma cells through the activation of ZEB1/vimentin axis. J Gastrointest Oncol 2023;14:2178-91. [Crossref] [PubMed]
- Sun B, Hu C, Yang Z, et al. Midkine promotes hepatocellular carcinoma metastasis by elevating anoikis resistance of circulating tumor cells. Oncotarget 2017;8:32523-35. [Crossref] [PubMed]
